Videos

In this video, Prof. Yi-Heng Li discusses the future of ASCVD and Lipidology in 2025.

Prof. Yi-Heng Li

First published: August 26, 2025  

In this video, Prof. Christopher P. Cannon presents an infographic on treatment persistence and non-adherence in Atherosclerotic Cardiovascular Disease.

Prof. Christopher P. Cannon

First published: July 16, 2025  

In this video, Prof. Deepak L. Bhatt presents an infographic on the role of eicosanoids in atherosclerosis with a focus on IPE as therapeutic option for CVD.

Prof. Deepak L. Bhatt

First published: May 29, 2025  

Check out our latest animated video to learn more about the one-year follow-up of the SANTORINI study.

First published: March 13, 2025  

In this video, Prof. Maciej Banach discusses the 2024 recommendations on the optimal use of LLT in established ASCVD and following ACS.

First published: March 4, 2025  

In this video, Prof. Christopher Cannon and Prof. Maciej Banach discuss the current status of lipid lowering therapy with a focus on combination therapy.

First published: March 4, 2025  

In this video, Prof Stephen Nicholls discusses the future of ASCVD and Lipidology in 2025.

First published: February 24, 2025  

Welcome to our latest video! This video explores the emerging role of inclisiran, a small interfering RNA (siRNA) therapeutic that targets PCSK9, in the management of atherosclerotic cardiovascular disease. The summary delves into the mechanism of actions of inclisiran, its safety profile, results from clinical trials and the latest data presented at the ESC congress.

First published: January 13, 2025  

Prof. Christopher Cannon, Prof. Maciej Banach

First published: November 24, 2024  

In this video, Prof. Deepak L. Bhatt presents an infographic on Proprotein Convertase Subtilisin/Kexin Type 9 in Cholesterol Homeostasis, Inflammation, and Thrombosis Associated with Cardiovascular Diseases – an overview of molecular functions and therapeutic strategies.

Prof. Deepak L. Bhatt

First published: September 10, 2024  

Video highlights from the European Society of Cardiology (ESC) Congress 2024, taking place in London from August 30 to September 2. Featuring faculty members Prof Stephen Nicholls, Prof Deepak Bhatt and Prof Yi-Heng Li, these clips provide invaluable insights and updates on cardiovascular research from ESC Congress 2024.

Prof Stephen Nicholls, Prof Yi-Heng Li

First published: August 30, 2024  

In this video, Prof. Christopher Cannon provides a comprehensive overview of our infographic on the therapeutic management of dyslipidaemia. Dyslipidaemia, a key risk factor for cardiovascular diseases, is conventionally managed through therapies targeting lipoproteins such as LDL, Lp(a), IDL + VLDL through small-molecule therapeutics. Despite their effectiveness, off-target events and poor patient compliance often pose significant challenges. Hence novel therapeutics, such as small interfering RNAs, antisense oligonucleotides, and monoclonal antibodies have been developed. These advancements highlight a significant step forward in the management of dyslipidaemia. Prof. Cannon emphasizes these main points in the video, aiming to guide clinicians in optimizing lipid-lowering therapy for cardiovascular risk prevention.

Prof. Christopher Cannon

First published: August 1, 2024